Association between aspirin resistance and indices of inflammation and platelet activity in patients with acute coronary syndrome
Öz
Purpose: Aspirin resistance (AR) has been linked to increased cardiovascular morbidity and mortality in patients with acute coronary syndrome (ACS). Both ACS and AR have also been associated with enhanced platelet activity and inflammatory responses. This study aimed to evaluate the power of the levels of uric acid (UA), non-high-density lipoprotein (non-HDL) cholesterol, high-sensitivity C-reactive protein (Hs-CRP), and gamma-glutamyltransferase (GGT) and the mean platelet volume (MPV), to predict AR in patients with ACS.
Materials and Methods: This study included543 patients with ACS. AR was identified by whole blood aggregometry. Predictors of AR were determined through multivariate regression analyses and the receiver operating characteristic (ROC) curve analysis.
Results: The levels of UA, GGT, non-HDL cholesterol, MPV, and Hs-CRP were significantly higher in patients with AR compared to those without AR (5.6±1.5 vs.6.8±3.1, 20 vs 34 (median), 162.3±43.2 vs. 143.2±37.1, 8.2 ±0.9 vs. 8.9 ±1.1, 5.0 vs 14.7 (median)). A multivariate regression analysis identified MPV, UA, Hs-CRP and presence of clopidogrel resistance as independent predictors of AR.
Conclusion: In patients with ACS, AR was found to be associated with elevated platelet activity and inflammation, suggesting that these factors might contribute to the development of AR or might be underlying mechanisms of AR. These findings highlight potential benefit of a routine workup to assess the oxidative status, inflammation, and thrombogenicity that may help risk stratification and treatment decision-making in clinical Practice, in patients with AR.
Anahtar Kelimeler
Aspirin resistance, uric acid, gamma-glutamyltransferase, non-high density lipoprotein and High-Sensitivity C-Reactive Protein
Kaynakça
- Nardin M, Verdoia M, Cao D, Nardin S, Kedhi E, Galasso G et al. Platelets and the atherosclerotic process: an overview of new markers of platelet activation and reactivity, and their implications in primary and secondary prevention. J Clin Med 2023;12:6074.
- Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circulation Journal 2019;83:1085-196.
- Russo I, Brookles CG, Barale C, Melchionda E, Mousavi AH, Biolè C et al. Current strategies to guide the antiplatelet therapy in acute coronary syndromes. Int J Mol Sci. 2024;25:3981.
- Foussas SG, Zairis MN, Tsirimpis VG, Makrygiannis SS, Patsourakos NG, Adamopoulou EN et al. The impact of aspirin resistance on the long‐term cardiovascular mortality in patients with non‐ST segment elevation acute coronary syndromes. Clin Cardiol. 2009;32:142-7.
- Li J, Song M, Jian Z, Guo W, Chen G, Jiang G et al. Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence. J Atheroscler Thromb. 2014;21:239-47.
- Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A. 1998;95::14540-45.
- Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol. 2009;104:227-33.
- Mangiacapra F, Barbato E. Residual platelet reactivity: predicting short-and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomark Med. 2010;4:421-34.
- Du G, Lin Q, Wang J. A brief review on the mechanisms of aspirin resistance. Int J Cardiol. 2016;220:21-26.
- Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-51.
